Key result
Antihypertensive therapy increases 5-year survival in malignant hypertension from 0% to 75%, but its benefits against coronary heart disease are less obvious than for stroke.
Population
Patients with malignant and nonmalignant hypertension
Design
Review
Authors
Loading...
Antihypertensive therapy markedly improves malignant hypertension survival yet offers less coronary protection than stroke reduction; leaves open mechanisms limiting CHD benefit.
Antihypertensive therapy significantly improves survival and reduces stroke and heart failure, but its suboptimal effect on coronary heart disease may be due to partially reversible pathology, inadequate blood pressure control, and adverse metabolic effects of certain drugs.
Lennart Hansson (1989) conducted a review in Hypertension. Antihypertensive therapy was evaluated. Antihypertensive therapy increases 5-year survival in malignant hypertension from 0% to 75%, but its benefits against coronary heart disease are less obvious than for stroke.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: